TreviTherapeutics, Inc. (TRVI)

Trevi Therapeutics, headquartered in New Haven, Connecticut, is a clinical-stage biopharmaceutical company focused on developing "Haduvio" (Nalbuphine ER) for chronic cough and pruritus. Led by CEO Jennifer Good, the company’s strategy is "The Chronic Cough Specialist"—targeting high unmet needs in "Chronic Cough in IPF" (Idiopathic Pulmonary Fibrosis) and "Refractory Chronic Cough." Its core strategy centers on "Advancing Phase 2b/3 Clinical Trials" and "Securing Strategic Partnerships." Trevi’s mission is to improve the lives of patients suffering from chronic sensory conditions. The company is currently a high-potential biotech player, utilizing its specialized focus on the opioid receptor system to lead the way in respiratory innovation.

TRVI Stock is a company operating in Healthcare & Biotechnology sector, publicly traded on the NASDAQ under the ticker symbol TRVI. Headquartered at 195 Church St, New Haven, CT 06510, USA, the company conducts business across multiple markets, including USA, providing products and services related to its core operations. Under the leadership of CEO Jennifer Good, TreviTherapeutics, Inc. focuses on business development and operational growth within its sector. Investors closely monitor TRVI stock for its price movements, market performance, and potential returns, as well as its role within the industry. For up-to-date TRVI stock price, market trends, and company-related news, traders and analysts regularly refer to established financial information sources.